

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2016 (07.07.2016)

(10) International Publication Number
WO 2016/109531 A1

- (51) **International Patent Classification:**
A61K 31/352 (2006.01) *A61K 31/05* (2006.01)
A61P 25/00 (2006.01)
- (21) **International Application Number:** PCT/US2015/067855
- (22) **International Filing Date:** 29 December 2015 (29.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 62/098,007 30 December 2014 (30.12.2014) US
- (71) **Applicant:** AXIM BIOTECHNOLOGIES, INC. [US/US]; 18 East 50th Street, 5th Floor, New York, New York 10022 (US).
- (72) **Inventors:** ANASTASSOV, George; 18 East 50th Street, 5th Floor, New York, New York 10022 (US). CHANGONER, Lekhram; Boelewerf 32, Unit 3, 2987 VD Ridderkerk (NL).
- (74) **Agent:** GLATZEL, Khanh, T; Premium IP Services, P.C., 1501 Granger Ave., Escondido, CA 92027 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:** — with international search report (Art. 21(3))



WO 2016/109531 A1

(54) **Title:** OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT

(57) **Abstract:** This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.

OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States Provisional Application No. 62/098,007, filed December 30, 2014, the entire contents of which are hereby incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

[0002] The present invention generally relates to ophthalmic solutions and uses thereof. The ophthalmic solutions treat glaucoma and conjunctival inflammation in human subjects.

Description of the Related Technology

[0003] Glaucoma is one of the leading causes of blindness worldwide. In the U.S. there are approximately 2.5 million sufferers of glaucoma. Glaucoma refers to a group of diseases that damage the eye's optic nerve and can result in vision loss and eventually, blindness. Glaucoma is caused by an increase in the intraocular pressure (IOP), which eventually leads to optic nerve degeneration and blindness.

[0004] In the front of the eye is an anterior chamber, wherein a clear fluid flows in and out continuously through a drainage angle at the meeting point of the iris and the cornea. When the drainage angle is affected, fluid does not drain fast enough or does not drain at all, causing a buildup in eye pressure. High pressure may cause damages to optic nerves, which in turn causes vision loss and blindness.

[0005] High blood pressure is a contributing factor to glaucoma. However, glaucoma may happen even without pressure buildup in the eye chamber. Glaucoma affects different ethnic groups differently. In the African-American population, glaucoma is the leading cause of blindness. The Hispanic population is also affected by glaucoma more than other ethnic groups.

[0006] Age-related macular degeneration (AMD) is a leading cause of vision loss among people age fifty (50) and older. In AMD, the macula, a small spot near the retina in the back of the ocular globe, is damaged. In patients with AMD, a blurred area in the central vision range appears

and grows, eventually resulting in a blind spot in the central vision. Treatments for intermediate and acute AMD include vitamin therapy, such as vitamin C, vitamin E, and supplement therapy, such as zinc, cupric oxide, or lutein and zeaxanthin supplements. However, effective treatments for AMD are still sought.

[0007] Conjunctivitis is the infection or inflammation of the transparent membrane (conjunctiva) that lines the eyelid and covers the white part of the eyeball. In conjunctivitis, small blood vessels in the conjunctiva are inflamed and appear to be pink or red.

[0008] Conjunctivitis is caused by bacterial or viral infection or by allergies. In infants, an incomplete open tear duct may cause conjunctivitis. Early treatment of conjunctivitis prevents spreading, as certain conjunctivitis conditions can be contagious.

[0009] The cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine. Isolated compounds from the cannabis plant include Δ^9 -tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not. Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids that have been isolated from the cannabis plant. Many researchers have confirmed the medicinal value of cannabinoids. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.

[0010] The IUPAC nomenclature of THC is (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol. CBD's IUPAC nomenclature is 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-1,3-diol. CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.

[0011] Cannabinoids can be isolated by extraction or pressing from cannabis plants. Plants in the cannabis genus include *Cannabis sativa*, *Cannabis ruderalis*, and *Cannabis indica*. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.

[0012] Nabilone (racemic(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol ((-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol)). These synthetic cannabinoids are being investigated for medicinal purposes. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.

[0013] Cannabinoids have neuroprotective properties, especially cannabidiol and cannabigerol. Glaucoma is essentially the damage of optic nerve, and cannabinoids are useful in treating this damage. Moreover, cannabinoids also lower IOP when consumed by pulmonary absorptions, intraoral, and intravenous applications.

[0014] In AMD, wherein macular degeneration is the main cause, cannabinoids have neuroprotective properties and may slow down the degeneration of optic nerves. Regeneration of the macula may be promoted with the use of cannabinoids.

[0015] Cannabinoids also have anti-inflammatory and anti-angiogenic properties. These properties may be utilized in ophthalmitis, wherein ophthalmic tissues are infected; or conjunctivitis, wherein ophthalmic membrane tissues are infected and/or inflamed.

[0016] Cannabigerol has anti-bacterial and anti-inflammatory properties, with fast acting mechanisms. Cannabidiol is also anti-bacterial, with a minimum inhibitory concentration at between 0.5 - 1 µg/mL for various *Staphylococcus aureus* strains. Tetrahydrocannabinol also has anti-inflammatory and anti-bacterial properties.

[0017] Various products containing cannabidiol have been marketed in recent years. Cannabidiol may be consumed by ingestion, by inhalation, or by transdermal delivery. THC, CBD, and CBG have been studied for treatment of various indications, including nausea, lack of appetite, pain, epilepsy, etc.

SUMMARY

[0018] The present invention generally relates to an ophthalmic solution comprising cannabinoids, specifically THC, CBD, and CBG at specific proportions, in an aqueous solution for treatment of glaucoma. The present invention also relates to an ophthalmic solution comprising

CBD and CBG dissolved in balanced saline solution for symptomatic relief of conjunctival inflammation.

ABBREVIATIONS

- [0019] AMD: Age-related macular degeneration
 [0020] CBC: Cannabichromene
 [0021] CBDV: Cannabidivarin
 [0022] CBD: Cannabidiol
 [0023] CBG: Cannabigerol
 [0024] IOP: Intraocular Pressure
 [0025] IUPAC: International Union of Pure and Applied Chemistry
 [0026] THC: Tetrahydrocannabinols

DETAILED DESCRIPTION OF CERTAIN INVENTIVE EMBODIMENTS

[0027] This present invention is capable of being embodied in various forms. The description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the attached claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0028] The word “cannabinoid” used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs (Δ^9 -tetrahydrocannabinol, Δ^8 -tetrahydrocannabinol, 6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-ol, (-)-(3S,4S)-7-hydroxy- Δ^6 -tetrahydrocannabinol-1,1-dimethylheptyl, (+)-(3S,4S)-7-hydroxy- Δ^6 -tetrahydrocannabinol, and Δ^8 -tetrahydrocannabinol-11-oic acid); certain piperidine analogs (e.g., (-)-(6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-6-methyl-1-3-[(R)-1-methyl-4-phenylbutoxy]-1,9-phenanthridinediol 1-acetate)); certain aminoalkylindole analogs (e.g., (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-

naphthelenyl-methanone); certain open pyran-ring analogs (e.g., 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, 3-benzendi-ol, and 4-(1,1-dimethylheptyl)-2,3'-dihydroxy-6'- α -(3-hydroxypropyl)-1',-2',3',4',5',6'-hexahydrobiphenyl), their salts, solvates, metabolites, and metabolic precursors.

[0029] The word "cannabidiol" refers to cannabidiol and cannabidiol derivatives. As used in this application, cannabidiol is obtained from industrial hemp extract with trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.

[0030] The word "cannabigerol" refers to cannabigerol and cannabigerol derivatives. As used in this application, cannabigerol is industrial hemp extract with trace amount of THC or from cannabis extract.

[0031] In embodiments, the eye drop solution comprises a combination of cannabinoids to treat glaucoma. The cannabinoids in this embodiment are THC, CBD, and CBG. All three cannabinoids (THC, CBD, and CBG) are present in solid form

[0032] Cannabinoids used in this preferred embodiment may be in powder form. Cannabinoids may be isolated and freeze dried from cannabinoid solution extracted from the *Cannabis sativa* L. plant. The resulting powder cannabinoid may be dissolved in a water based solution in the presence of emulsifiers and thickeners.

[0033] Cannabinoids as used in this embodiment may be substantially free from impurities. Impurities present in cannabinoid powder may be residues from plant materials. Typical purity of cannabinoid powder in dissolvable form is at between 98.0% and 99.9% by weight. Cannabinoid powder in this high purity form may be a white or off-white color.

[0034] THC, CBD, and CBG as used in these embodiments may be present in the eye drop solution in different concentrations. THC may be preferably present in the eye drop solution at 0.1 to 0.5 by weight percent, more preferably at 0.1 to 0.2 by weight percent. CBD may be present in the eye drop solution at 0.1 to 0.5 by weight percent, more preferably at 0.15 to 0.3 by weight percent. CBG may be present in the eye drop solution at 0.05 to 0.5 by weight percent, more preferably at 0.1 to 0.3 by weight percent.

[0035] Other ingredients may be added into the eye drop solutions, such as a thickener, a buffer, a pH adjusting agent, an antiseptic agent, or a solubilizer. Known methods to prepare eye drop solutions may be used.

[0036] The thickener in this embodiment may include cyclodextrins, hydroxymethyl cellulose or any other macrocyclic oligosaccharide, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxyvinyl polymer, polyvinylpyrrolidone, carboxymethyl cellulose, polyacrylic acid, sodium polyacrylate, and sodium alginate. The concentration of the thickener may be 0.1 to 2 by weight percent.

[0037] The buffer may include, for example, sodium phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium borate, potassium acetate, sodium acetate, sodium citrate, disodium citrate, sodium carbonate, and sodium hydrogen carbonate. The buffer agent may be present in sufficient quantity to keep the pH level near neutral.

[0038] The pH adjusting agent may include, for example, lactic acid, citric acid, phosphoric acid, and acetic acid, to reduce pH level; sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogen carbonate, to increase pH level.

[0039] An antiseptic agent may optionally be incorporated into the eye drop solution to treat conjunctival inflammation, if present, or for antiseptic purposes. The antiseptic agent may include, for example, benzalkonium chloride, benzodocinium bromide, chlorhexidine gluconate, benzethonium chloride, sorbic acid, potassium sorbate, methyl parahydroxybenzoate, ethyl parahydroxy benzoate, and butyl parahydrobenzoate. The antiseptic agent may be present in the eye drop solution at a therapeutically effective amount.

[0040] The solubilizer may include, for example, vegetable oils and fats or the like such as polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, polyvinyl alcohol, tyloxapol, polyoxyethylene, polyoxypropylene glycol, and soybean oil. The solubilizer concentration may be present preferably at 0.5 to 3 by weight percent.

[0041] The pH of the eye drop solution in this preferred embodiment is preferably adjusted from 6 to 8. Purified water may be the solvent for the eye drop solution.

[0042] In other embodiments, the eye drop solution may comprise cannabinoids, specifically CBD and CBG, to treat conjunctival inflammation. Each of CBD and CBG may be present at 0.05 to 0.5 by weight percent, more preferably at 0.1 to 0.3 by weight percent of the eye drop solution. CBD and CBG may be present at equal weight concentration in the eye drop solution according to these embodiments.

[0043] To facilitate dissolution of cannabinoids in the eye drop solution, cannabinoids may be encapsulated in liposomal capsules. Alternatively, cannabinoids may be freeze dried and dissolved in an alcohol solution to promote dissolution. Cannabinoids may also be complexed with β -cyclodextrin to increase dissolution rate in water-based solutions.

[0044] The ophthalmic solution according to these embodiments may be used to treat glaucoma in human subjects. The ophthalmic solution may be placed in a dropper container. A human subject may receive between 1 to 5 drops of the ophthalmic solution according to this embodiment in each of his or her eyes and then closes his or her eyes for at least 10 seconds. The human subject may repeat this application twice daily.

[0045] Other ingredients may be added into the eye drop solutions, such as a thickener, a buffer, a pH adjusting agent, or a solubilizer. The eye drop solution components may be dissolved in a balanced saline solution (BSS). Known methods to prepare eye drop solutions may be used.

[0046] The thickener in this embodiment may include cyclodextrins, hydroxymethyl cellulose or any other macrocyclic oligosaccharide, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxyvinyl polymer, polyvinylpyrrolidone, carboxymethyl cellulose, polyacrylic acid, sodium polyacrylate, and sodium alginate. The concentration of the thickener may be 0.1 to 2 by weight percent.

[0047] The buffer may include, for example, sodium phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium borate, potassium acetate, sodium acetate, sodium citrate, disodium citrate, sodium carbonate, and sodium hydrogen carbonate. The buffer agent may be in sufficient quantity to keep pH level near neutral.

[0048] The pH adjusting agent may include, for example, lactic acid, citric acid, phosphoric acid, acetic acid, to reduce pH level; sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogen carbonate, to increase pH level.

[0049] The solubilizer may include, for example, vegetable oils and fats or the like such as polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, polyvinyl alcohol, tyloxapol, polyoxyethylene, polyoxypropylene glycol, and soybean oil. The solubilizer concentration may be present at 0.5 to 3 by weight percent.

[0050] The pH of the eye drop solution in this preferred embodiment may be adjusted to 6 to 8. This eye drop solution may be based on a balanced saline solution.

[0051] The ophthalmic solution according to these embodiments may be used to treat conjunctivitis in human subjects. The ophthalmic solution according to this embodiment may be placed in a dropper container. A human subject may receive between 1 to 3 drops of the ophthalmic solution according to this embodiment in each of his or her eyes and then may close his or her eyes for at least 5 seconds. The human subject may repeat this application twice daily.

EXAMPLES

[0052] Example 1

Eye drop solution for glaucoma treatment

Raw material	Percentage (%)	Weight (g)
THC	0.15	1.5
CBD	0.25	2.5
CBG	0.25	2.5
Hydroxymethyl cellulose	0.2	2
Benzalkonium chloride	0.02	0.2
Polysorbate 80	1	10
Water	98.13	981.3
Total	100	1000

[0053] All ingredients as above, except for water, are weighed and added into a mixing flask. Add 970ml of purified water into the mixing flask. Place the flask on a heat and stirring plate, stir the mixture while heating to 70°C to allow dissolution. After returning to room temperature, the solution is made exactly 1000ml by adding purified water.

[0054] Example 2

Eye drop solution for glaucoma treatment

Raw material	Percentage (%)	Weight (g)
THC	0.15	1.5
CBD	0.25	2.5
CBG	0.25	2.5
Hydroxymethyl cellulose	0.2	2

Benzalkonium chloride	0.02	0.2
Polysorbate 80	1	10
Disodium dihydrogen phosphate dodecahydrate	0.1	1
Water	98.03	980.3
Total	100	1000

[0055] An eye drop solution for glaucoma treatment is prepared as in Example 1, but with 1g of disodium dihydrogen phosphate dodecahydrate added to stabilize the pH. Water added in the last step is adjusted accordingly to yield 1000ml of eye drop solution.

[0056] Example 3

Eye drop solution for conjunctival inflammation treatment

Raw material	Percentage (%)	Weight (g)
CBD	0.25	2.5
CBG	0.25	2.5
Hydroxymethyl cellulose	0.2	2
Polysorbate 80	1	10
Balanced saline solution	98.3	983
Total	100	1000

[0057] All ingredients as above, except for water, are weighed and added into a mixing flask. Add 970ml of balanced saline solution into the mixing flask. Place the flask on a heat and stirring plate, stir the mixture while heating to 70⁰C to allow dissolution. After returning to room temperature, the solution is made exactly 1000ml by adding purified water.

[0058] All references, including publications, patent applications, and patents cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0059] It will be readily apparent to those skilled in the art that a number of modifications and changes may be made without departing from the spirit and the scope of the present invention. It is to be understood that any ranges, ratios, and range of ratios that can be derived from any of the data disclosed herein represent further embodiments of the present disclosure and are included

as part of the disclosure as though they were explicitly set forth. This includes ranges that can be formed that do or do not include a finite upper and/or lower boundary. Accordingly, a person of ordinary skill in the art will appreciate that such values are unambiguously derivative from the data presented herein.

WHAT IS CLAIMED IS:

1. An ophthalmic solution for treatment of glaucoma comprising:
 - (a) Δ^9 - tetrahydrocannabinols, cannabidiol, and cannabigerol;
 - (b) a thickener selected from the group consisting of cyclodextrins, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxyvinyl polymer, polyvinylpyrrolidone, carboxymethyl cellulose, polyacrylic acid, sodium polyacrylate, and sodium alginate;
 - (c) a solubilizer selected from the group consisting of polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, polyvinyl alcohol, tyloxapol, polyoxyethylene, polyoxypropylene glycol, and soybean oil;
 - (d) a buffer selected from the group consisting of sodium phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium borate, potassium acetate, sodium acetate, sodium citrate, disodium citrate, sodium carbonate, and sodium hydrogen carbonate; and
 - (d) water.

2. The ophthalmic solution of Claim 1, wherein:
 - (a) Δ^9 - tetrahydrocannabinols is present in the ophthalmic solution at 0.1 to 0.5 weight percent;
 - (b) cannabidiol is present in the ophthalmic solution at 0.1 to 0.5 weight percent;and
 - (c) cannabigerol is present in ophthalmic solution at 0.05 to 0.5 weight percent.

3. The ophthalmic solution of Claim 1, wherein:
 - (a) Δ^9 - tetrahydrocannabinols is present in the ophthalmic solution at 0.1 to 0.2 weight percent;
 - (b) cannabidiol is present in the ophthalmic solution at 0.15 to 0.3 weight percent;and

(c) cannabigerol is present in ophthalmic solution at 0.1 to 0.3 weight percent.

4. The ophthalmic solution of Claim 1, wherein the thickener is present at 0.1 to 2 weight percent.

5. The ophthalmic solution of Claim 1, wherein the solubilizer is present at 0.5 to 3 weight percent.

6. The ophthalmic solution of Claim 1, further comprising an antiseptic agent.

7. The ophthalmic solution of Claim 6, wherein the antiseptic agent is selected from a group consisting of benzalkonium chloride, benzodocinium bromide, chlorhexidine gluconate, benzethonium chloride, sorbic acid, potassium sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, and butyl parahydrobenzoate.

8. The ophthalmic solution of Claim 6, further comprising a pH adjusting agent.

9. The ophthalmic solution of Claim 8, wherein the pH adjusting agent is selected from the group consisting of lactic acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogen carbonate.

10. Use of cannabinoids for the manufacture of a cannabinoid ophthalmic solution according to any of Claims 1 - 9 for the treatment of glaucoma.

11. An ophthalmic solution for treatment of conjunctivitis comprising:

(a) cannabidiol and cannabigerol;

(b) a thickener selected from the group consisting of cyclodextrins, hydroxymethyl cellulose or any other macrocyclic oligosaccharide, hydroxylpropyl methyl cellulose, hydroxylpropyl cellulose, polyvinyl alcohol, carboxyvinyl polymer, polyvinylpyrrolidone, carboxymethyl cellulose, polyacrylic acid, sodium polyacrylate, and sodium alginate;

(c) a solubilizer selected from the group consisting of polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, polyvinyl alcohol, tyloxapol, polyoxyethylene, polyoxypropylene glycol, and soybean oil;

(d) a buffer selected from the group consisting of sodium phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium borate, potassium acetate, sodium acetate, sodium citrate, disodium citrate, sodium carbonate, and sodium hydrogen carbonate; and

(e) a balanced saline solution.

12. The ophthalmic solution of Claim 11, wherein:

(a) cannabidiol is present at 0.05 to 0.5 weight percent; and

(b) cannabigerol is present at 0.05 to 0.5 weight percent.

13. The ophthalmic solution of Claim 11, wherein:

(a) cannabidiol is present at 0.1 to 0.3 weight percent; and

(b) cannabigerol is present at 0.1 to 0.3 weight percent.

14. The ophthalmic solution of Claim 11, further comprising a pH adjusting agent.

15. The ophthalmic solution of Claim 14, wherein the pH adjusting agent is selected from the group consisting of lactic acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogen carbonate.

16. The ophthalmic solution of Claim 11, wherein the thickener is present at 0.1 to 2 weight percent.

17. The ophthalmic solution of Claim 11, wherein the solubilizer is present at 0.5 to 3 weight percent.

18. Use of cannabinoids for the manufacture of a cannabinoid ophthalmic solution according to any of Claims 11 - 17 for the treatment of conjunctivitis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 15/67855

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61K 31/352, A61P 25/00, A61K 31/05 (2016.01) CPC - A61K 31/35 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC(8) - A61K 31/352, A61P 25/00, A61K 31/05 (2016.01) CPC - A61K 31/35 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched USPC - 514/454 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Patbase, Google Patents, Google Web Search terms used - ophthalmic solutions glaucoma conjunctivitis treatment cannabidiol cbd the eye drops canasol cannabigerol Pubchem substructure search		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 8,222,292 B2 (Goskonda et al.) 17 July 2012 (17.07.2012); col 6, ln 34-37, col 8, ln 19-20, col 10, col 11, ln 26-28, col 12, ln 7, ln 53, col 17, ln 4-10, ln 35, col 22, table 4, claim 4	1-10 -----
Y		11-18
Y	US 2010/0216872 A1 (Letzel et al.) 26 August 2010 (26.08.2010); para [0015], [0019]	11-18
A	US 2007/0249581 A1 (Chen et al.) 25 October 2007 (25.10.2007); entire document	1-18
A	US 2010/0273895 A1 (Stinchcomb et al.) 28 October 2010 (28.10.2010); entire document	1-18
A	US 6,630,507 B1 (Hampson et al.) 07 October 2003 (07.10.2003); entire document	1-18
A	"Hydroxypropyl-beta-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol." (Jarho et al.) Life Sciences. 15 October 1998 (15.10.1998) vol 63, pg. 381-384; entire document	1-18
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/>		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 23 February 2016		Date of mailing of the international search report 17 MAR 2016
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300		Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774